SEC Form 4 · accession 0001209191-17-057221
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas P. Lynch
Officer — EVP, Chief Admin Off, GC & Sec
Period of report
Oct 13, 2017
Accepted (ET)
Oct 17, 2017 · 7:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Unit (RSU)F2,F1,F3 | — | Oct 13, 2017 | A | 69,600 | A | — | — | Common Stock | 69,600 | 69,600 | D |
Explanation of responses
- F1Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
- F2Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement.
- F3Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eligibility on each applicable Vesting Date.